Regeneration of its Own
With the federal government readying to take a leadership role in funding stem cell research, the voter-created California Institute for Regenerative Medicine will need to rethink its role.

Running Over Roadblocks
France’s stem cell research policies are neither Europe’s easiest or toughest but the country has managed to make progress in regenerative technologies, despite restrictions. The current bioethics law is up for review, suggesting change may be ahead.

A New Tune
After years of watching the development of the emerging stem cell field from a distance, Big Pharma is starting to embrace the technology. One near-term payoff may come in new tools for drug development.

Cell Mates
CEO John Walker says iZumi’s collaboration with Kyoto University on pluripotent cells could ultimately lead to breakthroughs in drug development and therapeutics.

Gimme Shelter
A lab building boom is underway in California thanks to money raised by the state’s stem cell agency. The race is on as 12 institutions must complete building their state-of-the art research facilities by mid 2010.

Fishing for Biotech
Country and state economic development departments are going to great lengths to lure industry players.

Personalized Medicine's Achille's Heel
Some of the very things that are needed to make tailor-made therapies possible—including biomarkers and diagnostic screening tests—could be difficult to patent, threatening the field’s development.

In the Red
Although posting positive numbers in March, with the Burrill Biotech Select Index up 3.7 percent, biotech along with the rest of the general markets, took quite a pounding in the first quarter of 2009.

• US Biotech Financings
• Partnering Robust

• Australia
• Asia
• Europe
• Canada
• United States